{"protocolSection":{"identificationModule":{"nctId":"NCT02963935","orgStudyIdInfo":{"id":"NN8022-4274"},"secondaryIdInfos":[{"id":"U1111-1177-5059","type":"OTHER","domain":"World Health Organization (WHO)"}],"organization":{"fullName":"Novo Nordisk A/S","class":"INDUSTRY"},"briefTitle":"Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting","officialTitle":"Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting","acronym":"SCALE™ IBT"},"statusModule":{"statusVerifiedDate":"2020-02","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-02-06","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2018-05-23","type":"ACTUAL"},"completionDateStruct":{"date":"2018-06-19","type":"ACTUAL"},"studyFirstSubmitDate":"2016-11-10","studyFirstSubmitQcDate":"2016-11-10","studyFirstPostDateStruct":{"date":"2016-11-15","type":"ESTIMATED"},"resultsFirstSubmitDate":"2019-05-21","resultsFirstSubmitQcDate":"2019-07-08","resultsFirstPostDateStruct":{"date":"2019-07-30","type":"ACTUAL"},"lastUpdateSubmitDate":"2020-02-28","lastUpdatePostDateStruct":{"date":"2020-03-11","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Novo Nordisk A/S","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This trial is conducted in the United States of America (USA). The purpose of the trial is to investigate the effect and safety of liraglutide 3.0 mg as an adjunct to intensive behaviour therapy for obesity in a non-specialist setting (IBT-CMS: Intensive Behaviour Therapy for obesity in a primary care setting according to Centers for Medicare \\& Medicaid Services (CMS) visit schedule)."},"conditionsModule":{"conditions":["Metabolism and Nutrition Disorder","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":282,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Liraglutide","type":"EXPERIMENTAL","interventionNames":["Drug: liraglutide","Behavioral: CMS Intensive Behavior Therapy"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo","Behavioral: CMS Intensive Behavior Therapy"]}],"interventions":[{"type":"DRUG","name":"liraglutide","description":"Administered subcutaneously (s.c., under the skin) once daily for 56 weeks. Dose gradually increased to 3.0 mg","armGroupLabels":["Liraglutide"]},{"type":"DRUG","name":"placebo","description":"Administered subcutaneously (s.c., under the skin) once daily for 56 weeks. Dose gradually increased to 3.0 mg","armGroupLabels":["Placebo"]},{"type":"BEHAVIORAL","name":"CMS Intensive Behavior Therapy","description":"Intensive Behaviour Therapy for obesity","armGroupLabels":["Liraglutide","Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change in Body Weight (%)","description":"Observed mean change in body weight from baseline (week 0) to week 56 was evaluated for two different observation periods. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which subjects are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for AEs) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).\n\nThe test of superiority of liraglutide to placebo for the treatment policy estimand was tested in a hierarchical manner for the two primary and the consequent 7 confirmatory secondary endpoints presented.","timeFrame":"Week 0, week 56"},{"measure":"Proportion of Subjects Losing at Least 5% of Baseline Body Weight at Week 56","description":"The estimated mean percentage of subjects losing at least 5% of baseline body weight at week 56 is presented. The endpoint was evaluated based on in-trial data and on-drug data.","timeFrame":"Week 56"}],"secondaryOutcomes":[{"measure":"Proportion of Subjects Losing More Than 10% of Baseline Body Weight at Week 56","description":"The estimated mean percentage of subjects losing more than 10% of baseline body weight at week 56 is presented. The endpoint was evaluated based on in-trial data and on-drug data.","timeFrame":"Week 56"},{"measure":"Proportion of Subjects Losing More Than 15% of Baseline Body Weight at Week 56","description":"The estimated mean percentage of subjects losing more than 15% of baseline body weight at week 56 is presented. The endpoint was evaluated based on in-trial data and on-drug data.","timeFrame":"Week 56"},{"measure":"Proportion of Subjects Losing 4% or More of Baseline Body Weight","description":"The estimated mean percentage of subjects losing 4% or more of baseline body weight at week 16 is presented. The endpoint was evaluated for treatment policy estimand (in-trial data).","timeFrame":"Week 16"},{"measure":"Change in Waist Circumference (cm)","description":"Observed mean change from baseline in waist circumference. The endpoint was evaluated based on in-trial data and on-drug data.","timeFrame":"Week 0, week 56"},{"measure":"Change in Short Form-36 (SF-36) v2.0 Acute, Physical Functioning Score","description":"SF-36 is a 36-item patient-reported survey of patient health that measures the subject's overall health-related quality of life (HRQoL).\n\nSF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. Change from baseline in SF-36 physical functioning score is presented. A positive change score indicates an improvement since baseline. The endpoint was evaluated based on in-trial data and on-drug data.","timeFrame":"Week 0, week 56"},{"measure":"Change in IWQoL-Lite for CT, Physical Function Domain (5-items) Score","description":"Observed mean change in Impact of Weight on Quality of Life-Lite for Clinical Trials Version (IWQoL-Lite for CT ) score. IWQoL-Lite for CT (Weight on Quality of Life-Lite for Clinical Trial Version) is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life.\n\nThe endpoint was evaluated based on in-trial data and on-drug data.","timeFrame":"Week 0, week 56"},{"measure":"Change in Six Minutes Walking Distance Test (6MWT)","description":"Observed mean change from baseline in 6 minutes walking distance test. The 6MWT is a common test of functional exercise capacity that assesses the distance a subject can walk in 6 minutes. The endpoint was evaluated based on in-trial data and on-drug data.","timeFrame":"Week 0, week 56"},{"measure":"Change From Baseline in HbA1c (%)","description":"Observed mean change from baseline to week 56 in glycosylated haemoglobin (HbA1c). Results based on FAS in-trial data is presented.","timeFrame":"Week 0, week 56"},{"measure":"Change From Baseline in FPG (mg/dL)","description":"Observed mean change from baseline (week 0) in fasting plasma glucose (FPG). Results based on FAS in-trial data is presented.","timeFrame":"Week 0, week 56"},{"measure":"Change From Baseline sBP (mmHg)","description":"Observed mean change in systolic blood pressure from baseline to week 56.","timeFrame":"Week 0, week 56"},{"measure":"Change From Baseline dBP (mmHg)","description":"Observed mean change from baseline (week 0) to week 56 in diastolic blood pressure (dBP). Results based on FAS in-trial data is presented.","timeFrame":"Week 0, week 56"},{"measure":"Change From Baseline in Lipids -Total Cholesterol","description":"Observed mean change from baseline (week 0) to week 56 in total cholesterol (TC). Results based on FAS in-trial data is presented.","timeFrame":"Week 0, week 56"},{"measure":"Change From Baseline in Lipids - LDL Cholesterol","description":"Observed mean change from baseline in low density cholesterol (LDL) from baseline (week 0) to week 56. Results based on FAS in-trial data is presented.","timeFrame":"Week 0, week 56"},{"measure":"Change From Baseline in Lipids - HDL Cholesterol","description":"Observed mean change from baseline in high density (HDL) cholesterol from baseline (week 0) to week 56. Results based on FAS in-trial data is presented.","timeFrame":"Week 0, week 56"},{"measure":"Change From Baseline in Lipids - VLDL Cholesterol","description":"Observed mean change from baseline in very low density cholesterol (VLDL) from baseline (week 0) to week 56. Results based on FAS in-trial data is presented.","timeFrame":"Week 0, week 56"},{"measure":"Change From Baseline in Lipids - TG","description":"Observed mean change from baseline in triglyceride (TG) from baseline (week 0) to week 56. Results based on FAS in-trial data is presented.","timeFrame":"Week 0, week 56"},{"measure":"Change From Baseline in Lipids - FFA","description":"Observed mean change from baseline in free fatty acids (FFA) from baseline (week 0) to week 56. Results based on FAS in-trial data is presented.","timeFrame":"Week 0, week 56"},{"measure":"Change in Short Form-36 v2.0 Acute (SF-36) (Subdomains)","description":"SF-36 is a 36-item patient-reported survey of patient health that measures the subject's overall health-related quality of life (HRQoL).\n\nSF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. Change from baseline in in the sub-domain scores is presented. A positive change score indicates an improvement since baseline. Results are evaluated based on in-trial data.","timeFrame":"Week 0, week 56"},{"measure":"Change in Short Form-36 v2.0 Acute (SF-36) (Physical Component Summary (PCS))","description":"Observed mean change from baseline (week 0) to week 56 in short form 36 v2.0 acute domain physical component summary (PCS). SF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. Change from baseline in SF-36 physical component summary (PCS) score is presented. A positive change score indicates an improvement since baseline. The endpoint was evaluated based on in-trial data and on-drug data.","timeFrame":"Week 0, week 56"},{"measure":"Change in Short Form-36 v2.0 Acute (SF-36) (Mental Component Summary (MCS)","description":"Observed mean change from baseline (week 0) to week 56 in short form 36 v2.0 acute domain mental component summary (MCS). SF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. Change from baseline in SF-36 mental component summary is presented. A positive change score indicates an improvement since baseline. The endpoint was evaluated based on in-trial data and on-drug data.","timeFrame":"Week 0, week 56"},{"measure":"Change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT): Pain/Discomfort Domain Score","description":"Observed mean change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT) domain pain and discomfort. IWQoL-Lite for CT (Weight on Quality of Life-Lite for Clinical Trial Version) is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. Results based on FAS in-trial data is presented.","timeFrame":"Week 0, week 56"},{"measure":"Change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT): Psychosocial Domain Score","description":"Observed mean change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT) psychosocial domain. IWQoL-Lite for CT (Weight on Quality of Life-Lite for Clinical Trial Version) is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. Results based on FAS in-trial data is presented.","timeFrame":"Week 0, week 56"},{"measure":"Change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT): Total Score","description":"Observed mean change from baseline (week 0) to week 56 in IWQoL-Lite for CT total score. IWQoL-Lite for CT (Weight on Quality of Life-Lite for Clinical Trial Version) is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. Results based on FAS in-trial data is presented.","timeFrame":"Week 0, week 56"},{"measure":"Change in Weight Related Sign and Symptom (WRSS) Measure, Total Score","description":"Observed mean change from baseline (week 0) to week 56 in WRSS measure, total score. The WRSS measures the presence and bothersome associated with weight-related symptoms.\n\nThe WRSS questionnaire was not validated until after database lock. Therefore the total score couldn't be calculated and the supportive secondary endpoint \"Weight related sign and symptom (WRSS) measure, total score\" couldn't be analysed.","timeFrame":"Week 0, week 56"},{"measure":"Subjects Who After 56 Weeks Achieve (Yes/no): ≥ 4.3 T-score Points Increase From Baseline in SF-36 Physical Functioning Score","description":"Percentage of subjects who achieved ≥ 4.3 T-score points increase from baseline in SF-36 physical functioning score at week 56 is presented. Results based on FAS in-trial data is presented.","timeFrame":"Week 56"},{"measure":"Subjects Who After 56 Weeks Achieve (Yes/no): ≥ 3.8 T-score Points Increase From Baseline in SF-36 Physical Component Score","description":"Percentage of subjects who achieved ≥ 3.8 T-score points increase from baseline in SF-36 physical component score at week 56 is presented. Results based on FAS in-trial data is presented.","timeFrame":"Week 56"},{"measure":"Subjects Who After 56 Weeks Achieve (Yes/no): ≥ 4.6 T-score Points Increase From Baseline in SF-36 Mental Component Score","description":"Percentage of subjects who achieved ≥ 4.6 T-score points increase from baseline in SF-36 mental component score at week 56 is presented. Results based on FAS in-trial data is presented.","timeFrame":"Week 56"},{"measure":"Responder Definition Value for IWQoL-Lite for CT Physical Function Domain (5-items) Score","description":"Responder definition value for IWQoL-Lite for CT physical function domain (5-items) score' was defined as '≥ 20 responder definition value for IWQoL-Lite for CT physical function domain (5-items) score. Percentage of subjects considered IWQoL-Lite for CT physical function domain score responders (increase of ≥20 points) at week 56 is presented. Results based on FAS in-trial data is presented.","timeFrame":"Week 56"},{"measure":"Number of Weeks (Completed Calendar Weeks) From Randomisation to Week 56 Adherent to Trial Product","description":"Adherence to trial product is assessed regularly at CMS-IBT visits. The number of weeks from randomisation to week 56, adherent to trial product is presented.","timeFrame":"Week 0, week 56"},{"measure":"Number of Weeks (Completed Calendar Weeks) From Randomisation to Week 56 Adherent to Caloric Diet","description":"Adherence to caloric diet is assessed regularly at CMS-IBT visits. The number of weeks from randomisation to week 56, adherent to caloric diet is presented.","timeFrame":"Week 0, week 56"},{"measure":"Number of Weeks (Completed Calendar Weeks) From Randomisation to Week 56 Adherent to Physical Activity","description":"Adherence to physical activity is assessed regularly at CMS-IBT visits. The number of weeks from randomisation to week 56, adherent to physical activity is presented.","timeFrame":"Week 0, week 56"},{"measure":"Number of Weeks (Completed Calendar Weeks) From Randomisation to Week 56 Adherent to Caloric Diet and Physical Activity","description":"Adherence to caloric diet and physical activity is assessed regularly at CMS-IBT visits. The number of weeks from randomisation to week 56, adherent to caloric diet and physical activity is presented.","timeFrame":"Week 0, week 56"},{"measure":"Number of Weeks (Completed Calendar Weeks) From Randomisation to Week 56 Adherent to Caloric Diet, Physical Activity and Trial Product","description":"Adherence to caloric diet, physical activity and trial product is assessed regularly at CMS-IBT visits. The number of weeks from randomisation to week 56, adherent to caloric diet, physical activity and trial product is presented.","timeFrame":"Week 0, week 56"},{"measure":"AEs From Randomisation Until and Including the Follow-up Period","description":"Number of adverse events from randomisation to until the end of the post-treatment follow-up period (30 days). Results based on SAS on-drug data is presented.","timeFrame":"Week 0 to week 56+30 days"},{"measure":"Change in Physical Examination","description":"Observed change from baseline to week 56 in physical examination are categorised under parameters namely abdomen, gastrointestinal system, cardiovascular system, central and peripheral nervous system, general appearence, head, ears, eyes, nose, throat and neck, lymph node palpation, musculoskeletal system, respiratory system, skin and thyroid gland. The percentage of subjects assessed as normal, abnormal not clinically significant and abnormal clinically significant at baseline and week 56 is presented.","timeFrame":"Week 1, week 56"},{"measure":"Change in Resting Pulse","description":"Observed mean change in pulse rate measured at resting position is presented.","timeFrame":"Week 0, week 56"},{"measure":"Change in ECG","description":"The ECGs were interpreted by the investigator at baseline (week -1) and week 56 and categorised as normal, abnormal NCS or abnormal CS. Number of subjects in each ECG category at baseline and week 56 are presented.","timeFrame":"Week -1, week 56"},{"measure":"Change in Laboratory Measurements: Haematology (Haemoglobin Blood)","description":"Observed mean change from baseline in haematological parameter blood haemoglobin.","timeFrame":"Week 0, week 56"},{"measure":"Change in Laboratory Measurements: Haematology (Haematocrit Blood)","description":"Observed mean change from baseline in haematological parameter blood haematocrit. Haematocrit is presented as the percentage of red blood cells in total blood. Results based on SAS on-drug data is presented.","timeFrame":"Week 0, week 56"},{"measure":"Change in Laboratory Measurements: Haematology (Erythrocytes)","description":"Observed mean change from baseline in haematological parameter - erythrocytes.","timeFrame":"Week 0, week 56"},{"measure":"Change in Laboratory Measurements: Haematology (Thrombocytes and Leukocytes)","description":"Observed mean change from baseline in haematological parameters - thrombocytss and leukocytes.","timeFrame":"Week 0, week 56"},{"measure":"Change in Laboratory Measurements: Biochemistry (Albumin)","description":"Observed mean change from baseline in biochemical parameter - albumin. Results based on SAS on-drug data is presented.","timeFrame":"Week 0, week 56"},{"measure":"Change in Laboratory Measurements: Biochemistry (Alkaline Phosphatase, Alanine Aminotransferase, Amylase, Aspartate Aminotransferase and Lipase)","description":"Observed mean change from baseline in biochemical parameters - alkaline phosphatase, alanine aminotransferase, amylase, aspartate aminotransferase and lipase. Results based on SAS on-drug data is presented.","timeFrame":"Week 0, week 56"},{"measure":"Change in Laboratory Measurements: Biochemistry (Bilirubin and Creatinine)","description":"Observed mean change from baseline in biochemical parameters - bilirubin and creatinine. Results based on SAS on-drug data is presented.","timeFrame":"Week 0, week 56"},{"measure":"Change in Laboratory Measurements: Biochemistry (Total Calcium, Pottassium, Sodium and Urea)","description":"Observed mean change from baseline in biochemical parameters - total calcium, pottassium, sodium and urea. Results based on SAS on-drug data is presented.","timeFrame":"Week 0, week 56"},{"measure":"Change in Laboratory Measurements: Biochemistry (C-reactive Protein and Uric Acid)","description":"Observed mean change from baseline in biochemical parameters - high sensitive c-reactive protein and uric acid. Results based on SAS on-drug data is presented.","timeFrame":"Week 0, week 56"},{"measure":"Change in Laboratory Measurements: Biochemistry (Glomerular Filtration Rate, Serum)","description":"Observed mean change from baseline in biochemical parameters - estimated glomerular filtration rate. Serum GFR is estimated using MDRD formula . Results based on SAS on-drug data is presented.","timeFrame":"Week 0, week 56"},{"measure":"Change in Laboratory Measurements: Biochemistry (Calcitonin)","description":"Observed mean change from baseline in biochemical parameter - calcitonin. Results based on SAS on-drug data is presented.","timeFrame":"Week 0, week 56"},{"measure":"Change in Laboratory Measurements: Biochemistry (Thyroid Stimulating Hormone)","description":"Observed mean change from baseline in biochemical parameters - thyroid stimulating hormone. Results based on SAS on-drug data is presented.","timeFrame":"Week 0, week 56"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial\n* BMI above or equal to 30 kg/m\\^2\n* Male or female, age 18 years or older at the time of signing informed consent\n\nExclusion Criteria:\n\n* HbA1c (glycosylated haemoglobin) above or equal to 6.5% (at screening visit), or diagnosis of type 1 or type 2 diabetes mellitus\n* Recent history of cardiovascular disease (myocardial infarction or stroke within the past 6 months), severe congestive heart failure (NYHA class III, IV), or second degree or greater heart block\n* Personal or family history of Medullary Thyroid Carcinoma (MTC), or Multiple Endocrine Neoplasia type 2 (MEN2)\n* Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method (adequate contraceptive measure as required by local regulation or practice)\n* Use in past 90 days of medications known to induce significant weight loss (e.g., prescription weight loss medications) or weight gain (e.g., chronic use of oral steroids, second generation antipsychotics)\n* History of pancreatitis (acute or chronic)\n* History of major depressive disorder within the past 2 years\n* Any lifetime history of a suicide attempt\n* Inadequately treated blood pressure defined as Grade 3 hypertension or higher (Systolic above or equal to 180 mmHg or diastolic above or equal to 110 mmHg)\n* History of malignancy (except for non-melanoma skin cancer) within the past 5 years","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Novo Nordisk Investigational Site","city":"Jacksonville","state":"Florida","zip":"32205","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Novo Nordisk Investigational Site","city":"Plantation","state":"Florida","zip":"33324","country":"United States","geoPoint":{"lat":26.13421,"lon":-80.23184}},{"facility":"Novo Nordisk Investigational Site","city":"Chicago","state":"Illinois","zip":"60607","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Novo Nordisk Investigational Site","city":"Greensboro","state":"North Carolina","zip":"27408","country":"United States","geoPoint":{"lat":36.07264,"lon":-79.79198}},{"facility":"Novo Nordisk Investigational Site","city":"Salisbury","state":"North Carolina","zip":"28144","country":"United States","geoPoint":{"lat":35.67097,"lon":-80.47423}},{"facility":"Novo Nordisk Investigational Site","city":"Wadsworth","state":"Ohio","zip":"44281","country":"United States","geoPoint":{"lat":41.02561,"lon":-81.72985}},{"facility":"Novo Nordisk Investigational Site","city":"Philadelphia","state":"Pennsylvania","zip":"19104-3317","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"Novo Nordisk Investigational Site","city":"Charleston","state":"South Carolina","zip":"29425","country":"United States","geoPoint":{"lat":32.77632,"lon":-79.93275}},{"facility":"Novo Nordisk Investigational Site","city":"Dallas","state":"Texas","zip":"75251","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Novo Nordisk Investigational Site","city":"Arlington","state":"Virginia","zip":"22206","country":"United States","geoPoint":{"lat":38.88101,"lon":-77.10428}}]},"referencesModule":{"references":[{"pmid":"32090517","type":"RESULT","citation":"Wadden TA, Tronieri JS, Sugimoto D, Lund MT, Auerbach P, Jensen C, Rubino D. Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial. Obesity (Silver Spring). 2020 Mar;28(3):529-536. doi: 10.1002/oby.22726."}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"According to the Novo Nordisk disclosure commitment on novonordisk-trials.com","url":"http://novonordisk-trials.com/"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"All the subjects received Intensive Behaviour Therapy (IBT) for obesity in a primary care setting according to Centers for Medicare \\& Medicaid Services (CMS) visit schedule during the trial.","recruitmentDetails":"The trial was conducted at 17 sites in the United States.","groups":[{"id":"FG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"FG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"142"},{"groupId":"FG001","numSubjects":"140"}]},{"type":"COMPLETED","comment":"Completed without discontinuation of trial product","achievements":[{"groupId":"FG000","numSubjects":"114"},{"groupId":"FG001","numSubjects":"103"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"28"},{"groupId":"FG001","numSubjects":"37"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"6"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"6"}]},{"type":"Unclassified","reasons":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"22"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"BG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"142"},{"groupId":"BG001","value":"140"},{"groupId":"BG002","value":"282"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"45.4","spread":"11.6"},{"groupId":"BG001","value":"49","spread":"11.2"},{"groupId":"BG002","value":"47.2","spread":"11.5"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"119"},{"groupId":"BG001","value":"116"},{"groupId":"BG002","value":"235"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"47"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"5"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"49"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"112"},{"groupId":"BG001","value":"115"},{"groupId":"BG002","value":"227"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Body weight","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kg","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"108.5","spread":"22.1"},{"groupId":"BG001","value":"106.7","spread":"22.0"},{"groupId":"BG002","value":"107.6","spread":"22.0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Body Weight (%)","description":"Observed mean change in body weight from baseline (week 0) to week 56 was evaluated for two different observation periods. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which subjects are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for AEs) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).\n\nThe test of superiority of liraglutide to placebo for the treatment policy estimand was tested in a hierarchical manner for the two primary and the consequent 7 confirmatory secondary endpoints presented.","populationDescription":"Full analysis set included all randomised subjects. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"percent change","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"title":"In-trial observation period","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"141"},{"groupId":"OG001","value":"130"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-7.4","spread":"7.9"},{"groupId":"OG001","value":"-4.0","spread":"7.4"}]}]},{"title":"On-drug observation period","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"103"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-9.1","spread":"7.4"},{"groupId":"OG001","value":"-4.8","spread":"7.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Treatrment policy estimand. The hypothesis and the alternative are: H: μliraglutide ≥ μplacebo against the alternative HA: μliraglutide \\< μplacebo. μliraglutide and μplacebo denote the true mean of % weight change for liraglutide 3.0 mg and placebo group, respectively. Week 56 responses were analysed using an analysis of covariance model with treatment, BMI groups, and sex as factors and baseline body weight as covariate.","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"The treatment policy estimand evaluated the treatment effect (liraglutide 3.0 mg vs placebo) at week 56 for all randomised subjects regardless of premature discontinuation of trial product.","pValue":"0.0003","statisticalMethod":"ANCOVA","statisticalComment":"Missing observations were imputed from the placebo arm based on a jump to reference (x100) multiple imputation approach.","paramType":"Treatment difference","paramValue":"-3.45","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-5.31","ciUpperLimit":"-1.59","estimateComment":"Liraglutide 3.0 mg - placebo"},{"groupIds":["OG000","OG001"],"groupDescription":"Hypothetical estimand. Analysis of on-drug data before first drug discontinuation date using a mixed model for repeated measurements with treatment, BMI groups, and sex as factors and baseline body weight as covariate, all nested within visit.","nonInferiorityType":"OTHER","nonInferiorityComment":"The hypothetical estimand evaluated the treatment effect (liraglutide 3.0 mg vs placebo) for all randomised subjects assuming that all subjects remained on trial product (on-treatment principle)","pValue":"0.0000","statisticalMethod":"Mixed models repeated measurement (MMRM)","paramType":"Treatment difference","paramValue":"-4.59","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-6.54","ciUpperLimit":"-2.64","estimateComment":"Liraglutide 3.0 mg - placebo"}]},{"type":"PRIMARY","title":"Proportion of Subjects Losing at Least 5% of Baseline Body Weight at Week 56","description":"The estimated mean percentage of subjects losing at least 5% of baseline body weight at week 56 is presented. The endpoint was evaluated based on in-trial data and on-drug data.","populationDescription":"Full analysis set included all randomised subjects. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"title":"In-trial observation period","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"141"},{"groupId":"OG001","value":"130"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"61.47"},{"groupId":"OG001","value":"38.82"}]}]},{"title":"On-drug observation period","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"64.08"},{"groupId":"OG001","value":"38.57"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Treatment policy estimand. Week 56 responses were analysed using a logistic regression model with treatment, BMI groups, and sex as factors and baseline body weight as covariate. Analysis of in-trial data with missing observations imputed from the placebo arm based on a jump to reference multiple (x100) imputation approach.","nonInferiorityType":"SUPERIORITY","pValue":"0.0003","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"2.51","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.53","ciUpperLimit":"4.14","estimateComment":"Liraglutide 3.0 mg/Placebo"},{"groupIds":["OG000","OG001"],"groupDescription":"Hypothetical estimand. Analysis of on-drug before first drug discontinuation date using a mixed model for repeated measurements with treatment, BMI groups, and sex as factors and baseline body weight as covariate, all nested within visit. The MMRM was used to classify responders and analysed with a logistic regression with treatment as the only factor.","nonInferiorityType":"OTHER","pValue":"0.0000","statisticalMethod":"Mixed models repeated measurement (MMRM)","paramType":"Odds Ratio (OR)","paramValue":"2.84","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.75","ciUpperLimit":"4.61","estimateComment":"Liraglutide 3.0 mg/placebo"}]},{"type":"SECONDARY","title":"Proportion of Subjects Losing More Than 10% of Baseline Body Weight at Week 56","description":"The estimated mean percentage of subjects losing more than 10% of baseline body weight at week 56 is presented. The endpoint was evaluated based on in-trial data and on-drug data.","populationDescription":"Full analysis set included all randomised subjects. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"title":"In-trial observation period","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"141"},{"groupId":"OG001","value":"130"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"30.45"},{"groupId":"OG001","value":"19.75"}]}]},{"title":"On-drug observation period","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.80"},{"groupId":"OG001","value":"19.29"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Treatment policy estimand. Week 56 responses were analysed using a logistic regression model with treatment, BMI groups, and sex as factors and baseline body weight as covariate. Analysis of in-trial data with missing observations imputed from the placebo arm based on a jump to reference multiple (x10000) imputation approach.","nonInferiorityType":"SUPERIORITY","pValue":"0.0469","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"1.78","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.01","ciUpperLimit":"3.14","estimateComment":"Liraglutide 3.0 mg/Placebo"},{"groupIds":["OG000","OG001"],"groupDescription":"Hypothetical estimand. Analysis of on-drug before first drug discontinuation date using a mixed model for repeated measurements with treatment, BMI groups, and sex as factors and baseline body weight as covariate, all nested within visit. The MMRM was used to classify responders and analysed with a logistic regression with treatment as the only factor.","nonInferiorityType":"OTHER","pValue":"0.0063","statisticalMethod":"Mixed models repeated measurement (MMRM)","paramType":"Odds Ratio (OR)","paramValue":"2.14","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.24","ciUpperLimit":"3.69","estimateComment":"Liraglutide 3.0 mg/placebo"}]},{"type":"SECONDARY","title":"Proportion of Subjects Losing More Than 15% of Baseline Body Weight at Week 56","description":"The estimated mean percentage of subjects losing more than 15% of baseline body weight at week 56 is presented. The endpoint was evaluated based on in-trial data and on-drug data.","populationDescription":"Full analysis set included all randomised subjects. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"title":"In-trial observation period","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"141"},{"groupId":"OG001","value":"130"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18.11"},{"groupId":"OG001","value":"8.92"}]}]},{"title":"On-drug observation period","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20.42"},{"groupId":"OG001","value":"8.57"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Treatment policy estimand. Week 56 responses were analysed using a logistic regression model with treatment, BMI groups, and sex as factors and baseline body weight as covariate. Analysis of in-trial data with missing observations imputed from the placebo arm based on a jump to reference multiple (x100) imputation approach.","nonInferiorityType":"SUPERIORITY","pValue":"0.0311","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"2.26","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.08","ciUpperLimit":"4.74","estimateComment":"Liraglutide 3.0 mg/Placebo"},{"groupIds":["OG000","OG001"],"groupDescription":"Hypothetical estimand. Analysis of on-drug before first drug discontinuation date using a mixed model for repeated measurements with treatment, BMI groups, and sex as factors and baseline body weight as covariate, all nested within visit. The MMRM was used to classify responders and analysed with a logistic regression with treatment as the only factor.","nonInferiorityType":"OTHER","pValue":"0.0060","statisticalMethod":"Mixed models repeated measurement (MMRM)","paramType":"Odds Ratio (OR)","paramValue":"2.74","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.33","ciUpperLimit":"5.62","estimateComment":"Liraglutide 3.0 mg/placebo"}]},{"type":"SECONDARY","title":"Proportion of Subjects Losing 4% or More of Baseline Body Weight","description":"The estimated mean percentage of subjects losing 4% or more of baseline body weight at week 16 is presented. The endpoint was evaluated for treatment policy estimand (in-trial data).","populationDescription":"Full analysis set included all randomised subjects. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Week 16","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.73"},{"groupId":"OG001","value":"52.70"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Treatment policy estimand. Week 16 responders were analysed using a logistic regression model with treatment, BMI groups, and sex as factors and baseline body weight as covariate.\n\nMissing values are considered as non-responders.","nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"3.32","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.93","ciUpperLimit":"5.72","estimateComment":"Liraglutide 3.0 mg/placebo"}]},{"type":"SECONDARY","title":"Change in Waist Circumference (cm)","description":"Observed mean change from baseline in waist circumference. The endpoint was evaluated based on in-trial data and on-drug data.","populationDescription":"Full analysis set included all randomised subjects. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"cm","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"title":"In-trial observation period","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"141"},{"groupId":"OG001","value":"127"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-9.27","spread":"9.22"},{"groupId":"OG001","value":"-6.91","spread":"8.22"}]}]},{"title":"On-drug observation period","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"103"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-10.46","spread":"9.22"},{"groupId":"OG001","value":"-7.24","spread":"8.67"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Analysis of in-trial data with missing observations imputed from the placebo arm based on a jump to reference multiple (x100) imputation approach. Week 56 responses were analysed using an analysis of covariance model with treatment, BMI groups, and sex as factors and baseline measurement of endpoint as covariate.","nonInferiorityType":"SUPERIORITY","pValue":"0.0063","statisticalMethod":"ANCOVA","paramType":"treatment difference","paramValue":"-2.72","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.68","ciUpperLimit":"-0.77","estimateComment":"Liraglutide 3.0 mg - placebo"},{"groupIds":["OG000","OG001"],"groupDescription":"Analysis of on-drug before first drug discontinuation date using a mixed model for repeated measurements with treatment, BMI groups, and sex as factors and baseline measurement of endpoint as covariate, all nested within visit.","nonInferiorityType":"OTHER","pValue":"0.0020","statisticalMethod":"Mixed model repeated measurements (MMRM)","paramType":"Treatment difference","paramValue":"-3.45","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-5.62","ciUpperLimit":"-1.28","estimateComment":"Liraglutide 3.0 mg - placebo"}]},{"type":"SECONDARY","title":"Change in Short Form-36 (SF-36) v2.0 Acute, Physical Functioning Score","description":"SF-36 is a 36-item patient-reported survey of patient health that measures the subject's overall health-related quality of life (HRQoL).\n\nSF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. Change from baseline in SF-36 physical functioning score is presented. A positive change score indicates an improvement since baseline. The endpoint was evaluated based on in-trial data and on-drug data.","populationDescription":"Full analysis set included all randomised subjects. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Scores on a scale","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"title":"In-trial observation period","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"121"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.55","spread":"6.98"},{"groupId":"OG001","value":"4.21","spread":"6.85"}]}]},{"title":"On-drug observation period","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"103"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.03","spread":"6.49"},{"groupId":"OG001","value":"4.77","spread":"6.03"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Treatment policy estimand. Analysis of in-trial data with missing observations imputed from the placebo arm based on a jump to reference multiple (x100) imputation approach. Week 56 responses were analysed using an analysis of covariance model with treatment, BMI groups, and sex as factors and baseline measurement of endpoint as covariate.","nonInferiorityType":"SUPERIORITY","pValue":"0.8137","statisticalMethod":"ANCOVA","paramType":"Treatment difference","paramValue":"0.16","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.19","ciUpperLimit":"1.52","estimateComment":"Liraglutide 3.0 mg - placebo"},{"groupIds":["OG000","OG001"],"groupDescription":"Hypothetical estimand. Analysis of on-drug before first drug discontinuation date using a mixed model for repeated measurements with treatment, BMI groups, and sex as factors and baseline measurement of endpoint as covariate, all nested within visit.","nonInferiorityType":"OTHER","pValue":"0.8053","statisticalMethod":"Mixed model repeated measurements (MMRM)","paramType":"Treatment difference","paramValue":"0.16","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.12","ciUpperLimit":"1.43","estimateComment":"Liraglutide 3.0 mg- placebo"}]},{"type":"SECONDARY","title":"Change in IWQoL-Lite for CT, Physical Function Domain (5-items) Score","description":"Observed mean change in Impact of Weight on Quality of Life-Lite for Clinical Trials Version (IWQoL-Lite for CT ) score. IWQoL-Lite for CT (Weight on Quality of Life-Lite for Clinical Trial Version) is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life.\n\nThe endpoint was evaluated based on in-trial data and on-drug data.","populationDescription":"Full analysis set included all randomised subjects. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Scores on a scale","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"title":"In-trial observation period","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"121"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13.5","spread":"21.4"},{"groupId":"OG001","value":"15.5","spread":"23.0"}]}]},{"title":"On-drug observation period","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"103"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.2","spread":"21.4"},{"groupId":"OG001","value":"17.5","spread":"21.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Treatment policy estimand. Analysis of in-trial data with missing observations imputed from the placebo arm based on a jump to reference multiple (x100) imputation approach. Week 56 responses were analysed using an analysis of covariance model with treatment, BMI groups, and sex as factors and baseline measurement of endpoint as covariate.","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Superiority was not tested as part of confirmatory testing strategy.","pValue":"0.6916","statisticalMethod":"ANCOVA","paramType":"Treatment difference","paramValue":"0.87","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.41","ciUpperLimit":"5.14","estimateComment":"Liraglutide 3.0 mg - placebo"},{"groupIds":["OG000","OG001"],"groupDescription":"Hypothetical estimand. Analysis of on-drug before first drug discontinuation date using a mixed model for repeated measurements with treatment, BMI groups, and sex as factors and baseline measurement of endpoint as covariate, all nested within visit.","nonInferiorityType":"OTHER","pValue":"0.5572","statisticalMethod":"Mixed models repeated measurements (MMRM","paramType":"treatment difference","paramValue":"1.25","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.95","ciUpperLimit":"5.45","estimateComment":"Liraglutide 3.0 mg - placebo"}]},{"type":"SECONDARY","title":"Change in Six Minutes Walking Distance Test (6MWT)","description":"Observed mean change from baseline in 6 minutes walking distance test. The 6MWT is a common test of functional exercise capacity that assesses the distance a subject can walk in 6 minutes. The endpoint was evaluated based on in-trial data and on-drug data.","populationDescription":"Full analysis set included all randomised subjects. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"meter","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"title":"In-trial observation period","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"116"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":"59"},{"groupId":"OG001","value":"49","spread":"69"}]}]},{"title":"On-drug observation period","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"112"},{"groupId":"OG001","value":"101"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":"61"},{"groupId":"OG001","value":"51","spread":"69"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Treatment policy estimand. Analysis of in-trial data with missing observations imputed from the placebo arm based on a jump to reference multiple (x100) imputation approach. Week 56 responses were analysed using an analysis of covariance model with treatment, BMI groups, and sex as factors and baseline measurement of endpoint as covariate.","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Superiority was not tested as part of confirmatory testing strategy.","pValue":"0.6986","statisticalMethod":"ANCOVA","paramType":"Treatment difference","paramValue":"3.12","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-12.68","ciUpperLimit":"18.92","estimateComment":"Liraglutide 3.0 mg - placebo"},{"groupIds":["OG000","OG001"],"groupDescription":"Hypothetical estimand. Analysis of on-drug before first drug discontinuation date using a mixed model for repeated measurements with treatment, BMI groups, and sex as factors and baseline measurement of endpoint as covariate, all nested within visit.","nonInferiorityType":"OTHER","pValue":"0.3700","statisticalMethod":"Mixed model repeated measurements (MMRM)","paramType":"Treatment difference","paramValue":"7.66","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-9.15","ciUpperLimit":"24.48","estimateComment":"Liraglutide 3.0 mg - placebo"}]},{"type":"SECONDARY","title":"Change From Baseline in HbA1c (%)","description":"Observed mean change from baseline to week 56 in glycosylated haemoglobin (HbA1c). Results based on FAS in-trial data is presented.","populationDescription":"Full analysis set included all randomised subjects. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"percentage","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.3"},{"groupId":"OG001","value":"-0.1","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in FPG (mg/dL)","description":"Observed mean change from baseline (week 0) in fasting plasma glucose (FPG). Results based on FAS in-trial data is presented.","populationDescription":"Full analysis set included all randomised subjects. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mg/dL","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.04","spread":"9.59"},{"groupId":"OG001","value":"-0.28","spread":"11.46"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline sBP (mmHg)","description":"Observed mean change in systolic blood pressure from baseline to week 56.","populationDescription":"Full analysis set included all randomised subjects. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmHg","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2","spread":"14"},{"groupId":"OG001","value":"-1","spread":"13"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline dBP (mmHg)","description":"Observed mean change from baseline (week 0) to week 56 in diastolic blood pressure (dBP). Results based on FAS in-trial data is presented.","populationDescription":"Full analysis set included all randomised subjects. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmHg","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1","spread":"11"},{"groupId":"OG001","value":"-1","spread":"10"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Lipids -Total Cholesterol","description":"Observed mean change from baseline (week 0) to week 56 in total cholesterol (TC). Results based on FAS in-trial data is presented.","populationDescription":"Full analysis set included all randomised subjects. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"0.59"},{"groupId":"OG001","value":"0.00","spread":"0.77"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Lipids - LDL Cholesterol","description":"Observed mean change from baseline in low density cholesterol (LDL) from baseline (week 0) to week 56. Results based on FAS in-trial data is presented.","populationDescription":"Full analysis set included all randomised subjects. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"0.52"},{"groupId":"OG001","value":"-0.01","spread":"0.64"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Lipids - HDL Cholesterol","description":"Observed mean change from baseline in high density (HDL) cholesterol from baseline (week 0) to week 56. Results based on FAS in-trial data is presented.","populationDescription":"Full analysis set included all randomised subjects. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.19"},{"groupId":"OG001","value":"0.02","spread":"0.22"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Lipids - VLDL Cholesterol","description":"Observed mean change from baseline in very low density cholesterol (VLDL) from baseline (week 0) to week 56. Results based on FAS in-trial data is presented.","populationDescription":"Full analysis set included all randomised subjects. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.06","spread":"0.31"},{"groupId":"OG001","value":"-0.01","spread":"0.26"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Lipids - TG","description":"Observed mean change from baseline in triglyceride (TG) from baseline (week 0) to week 56. Results based on FAS in-trial data is presented.","populationDescription":"Full analysis set included all randomised subjects. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.19","spread":"1.04"},{"groupId":"OG001","value":"-0.01","spread":"0.58"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Lipids - FFA","description":"Observed mean change from baseline in free fatty acids (FFA) from baseline (week 0) to week 56. Results based on FAS in-trial data is presented.","populationDescription":"Full analysis set included all randomised subjects. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.07","spread":"0.28"},{"groupId":"OG001","value":"-0.06","spread":"0.31"}]}]}]},{"type":"SECONDARY","title":"Change in Short Form-36 v2.0 Acute (SF-36) (Subdomains)","description":"SF-36 is a 36-item patient-reported survey of patient health that measures the subject's overall health-related quality of life (HRQoL).\n\nSF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. Change from baseline in in the sub-domain scores is presented. A positive change score indicates an improvement since baseline. Results are evaluated based on in-trial data.","populationDescription":"Full analysis set included all randomised subjects. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"scores on a scale","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"title":"Bodily Pain","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"121"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":"7.61"},{"groupId":"OG001","value":"1.21","spread":"8.88"}]}]},{"title":"General Health Perception","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"121"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.89","spread":"6.31"},{"groupId":"OG001","value":"1.08","spread":"6.62"}]}]},{"title":"Mental Health","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"121"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.93","spread":"7.80"},{"groupId":"OG001","value":"-0.68","spread":"6.89"}]}]},{"title":"Role Lim Emotion Prob","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"121"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.27","spread":"7.72"},{"groupId":"OG001","value":"-2.21","spread":"8.59"}]}]},{"title":"Role Lim. Phy Health","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"121"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.01","spread":"6.55"},{"groupId":"OG001","value":"2.11","spread":"7.68"}]}]},{"title":"Social Functioning","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"121"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.22","spread":"8.69"},{"groupId":"OG001","value":"-0.45","spread":"9.61"}]}]},{"title":"Vitality","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"121"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.64","spread":"8.99"},{"groupId":"OG001","value":"2.43","spread":"7.78"}]}]}]},{"type":"SECONDARY","title":"Change in Short Form-36 v2.0 Acute (SF-36) (Physical Component Summary (PCS))","description":"Observed mean change from baseline (week 0) to week 56 in short form 36 v2.0 acute domain physical component summary (PCS). SF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. Change from baseline in SF-36 physical component summary (PCS) score is presented. A positive change score indicates an improvement since baseline. The endpoint was evaluated based on in-trial data and on-drug data.","populationDescription":"Full analysis set included all randomised subjects. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"scores on a scale","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.41","spread":"6.65"},{"groupId":"OG001","value":"3.83","spread":"7.22"}]}]}]},{"type":"SECONDARY","title":"Change in Short Form-36 v2.0 Acute (SF-36) (Mental Component Summary (MCS)","description":"Observed mean change from baseline (week 0) to week 56 in short form 36 v2.0 acute domain mental component summary (MCS). SF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. Change from baseline in SF-36 mental component summary is presented. A positive change score indicates an improvement since baseline. The endpoint was evaluated based on in-trial data and on-drug data.","populationDescription":"Full analysis set included all randomised subjects. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"scores on a scale","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.22","spread":"8.74"},{"groupId":"OG001","value":"-2.20","spread":"8.11"}]}]}]},{"type":"SECONDARY","title":"Change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT): Pain/Discomfort Domain Score","description":"Observed mean change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT) domain pain and discomfort. IWQoL-Lite for CT (Weight on Quality of Life-Lite for Clinical Trial Version) is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. Results based on FAS in-trial data is presented.","populationDescription":"Full analysis set included all randomised subjects. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"scores on a scale","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.1","spread":"21.2"},{"groupId":"OG001","value":"8.6","spread":"23.1"}]}]}]},{"type":"SECONDARY","title":"Change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT): Psychosocial Domain Score","description":"Observed mean change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT) psychosocial domain. IWQoL-Lite for CT (Weight on Quality of Life-Lite for Clinical Trial Version) is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. Results based on FAS in-trial data is presented.","populationDescription":"Full analysis set included all randomised subjects. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.5","spread":"20.3"},{"groupId":"OG001","value":"12.4","spread":"21.8"}]}]}]},{"type":"SECONDARY","title":"Change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT): Total Score","description":"Observed mean change from baseline (week 0) to week 56 in IWQoL-Lite for CT total score. IWQoL-Lite for CT (Weight on Quality of Life-Lite for Clinical Trial Version) is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. Results based on FAS in-trial data is presented.","populationDescription":"Full analysis set included all randomised subjects. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"scores on a scale","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.2","spread":"18.5"},{"groupId":"OG001","value":"12.8","spread":"20.7"}]}]}]},{"type":"SECONDARY","title":"Change in Weight Related Sign and Symptom (WRSS) Measure, Total Score","description":"Observed mean change from baseline (week 0) to week 56 in WRSS measure, total score. The WRSS measures the presence and bothersome associated with weight-related symptoms.\n\nThe WRSS questionnaire was not validated until after database lock. Therefore the total score couldn't be calculated and the supportive secondary endpoint \"Weight related sign and symptom (WRSS) measure, total score\" couldn't be analysed.","populationDescription":"Full analysis set included all randomised subjects. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Score on a scale","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA","comment":"The WRSS questionnaire was not validated until after database lock. Therefore the total score couldn't be calculated and the supportive secondary endpoint \"Weight related sign and symptom (WRSS) measure, total score\" couldn't be analysed."},{"groupId":"OG001","value":"NA","spread":"NA","comment":"The WRSS questionnaire was not validated until after database lock. Therefore the total score couldn't be calculated and the supportive secondary endpoint \"Weight related sign and symptom (WRSS) measure, total score\" couldn't be analysed."}]}]}]},{"type":"SECONDARY","title":"Subjects Who After 56 Weeks Achieve (Yes/no): ≥ 4.3 T-score Points Increase From Baseline in SF-36 Physical Functioning Score","description":"Percentage of subjects who achieved ≥ 4.3 T-score points increase from baseline in SF-36 physical functioning score at week 56 is presented. Results based on FAS in-trial data is presented.","populationDescription":"Full analysis set included all randomised subjects. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.7"},{"groupId":"OG001","value":"37.9"}]}]}]},{"type":"SECONDARY","title":"Subjects Who After 56 Weeks Achieve (Yes/no): ≥ 3.8 T-score Points Increase From Baseline in SF-36 Physical Component Score","description":"Percentage of subjects who achieved ≥ 3.8 T-score points increase from baseline in SF-36 physical component score at week 56 is presented. Results based on FAS in-trial data is presented.","populationDescription":"Full analysis set included all randomised subjects. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.7"},{"groupId":"OG001","value":"41.4"}]}]}]},{"type":"SECONDARY","title":"Subjects Who After 56 Weeks Achieve (Yes/no): ≥ 4.6 T-score Points Increase From Baseline in SF-36 Mental Component Score","description":"Percentage of subjects who achieved ≥ 4.6 T-score points increase from baseline in SF-36 mental component score at week 56 is presented. Results based on FAS in-trial data is presented.","populationDescription":"Full analysis set included all randomised subjects. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.4"},{"groupId":"OG001","value":"9.3"}]}]}]},{"type":"SECONDARY","title":"Responder Definition Value for IWQoL-Lite for CT Physical Function Domain (5-items) Score","description":"Responder definition value for IWQoL-Lite for CT physical function domain (5-items) score' was defined as '≥ 20 responder definition value for IWQoL-Lite for CT physical function domain (5-items) score. Percentage of subjects considered IWQoL-Lite for CT physical function domain score responders (increase of ≥20 points) at week 56 is presented. Results based on FAS in-trial data is presented.","populationDescription":"Full analysis set included all randomised subjects. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.3"},{"groupId":"OG001","value":"34.3"}]}]}]},{"type":"SECONDARY","title":"Number of Weeks (Completed Calendar Weeks) From Randomisation to Week 56 Adherent to Trial Product","description":"Adherence to trial product is assessed regularly at CMS-IBT visits. The number of weeks from randomisation to week 56, adherent to trial product is presented.","populationDescription":"Full analysis set included all randomised subjects. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"weeks","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.5","spread":"14.0"},{"groupId":"OG001","value":"46.8","spread":"16.1"}]}]}]},{"type":"SECONDARY","title":"Number of Weeks (Completed Calendar Weeks) From Randomisation to Week 56 Adherent to Caloric Diet","description":"Adherence to caloric diet is assessed regularly at CMS-IBT visits. The number of weeks from randomisation to week 56, adherent to caloric diet is presented.","populationDescription":"Full analysis set included all randomised subjects. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"weeks","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.4","spread":"16.0"},{"groupId":"OG001","value":"36.1","spread":"17.3"}]}]}]},{"type":"SECONDARY","title":"Number of Weeks (Completed Calendar Weeks) From Randomisation to Week 56 Adherent to Physical Activity","description":"Adherence to physical activity is assessed regularly at CMS-IBT visits. The number of weeks from randomisation to week 56, adherent to physical activity is presented.","populationDescription":"Full analysis set included all randomised subjects. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"weeks","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.0","spread":"17.1"},{"groupId":"OG001","value":"30.0","spread":"17.2"}]}]}]},{"type":"SECONDARY","title":"Number of Weeks (Completed Calendar Weeks) From Randomisation to Week 56 Adherent to Caloric Diet and Physical Activity","description":"Adherence to caloric diet and physical activity is assessed regularly at CMS-IBT visits. The number of weeks from randomisation to week 56, adherent to caloric diet and physical activity is presented.","populationDescription":"Full analysis set included all randomised subjects. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"weeks","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.0","spread":"16.0"},{"groupId":"OG001","value":"24.5","spread":"15.7"}]}]}]},{"type":"SECONDARY","title":"Number of Weeks (Completed Calendar Weeks) From Randomisation to Week 56 Adherent to Caloric Diet, Physical Activity and Trial Product","description":"Adherence to caloric diet, physical activity and trial product is assessed regularly at CMS-IBT visits. The number of weeks from randomisation to week 56, adherent to caloric diet, physical activity and trial product is presented.","populationDescription":"Full analysis set included all randomised subjects. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"weeks","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.9","spread":"16.1"},{"groupId":"OG001","value":"24.0","spread":"15.9"}]}]}]},{"type":"SECONDARY","title":"AEs From Randomisation Until and Including the Follow-up Period","description":"Number of adverse events from randomisation to until the end of the post-treatment follow-up period (30 days). Results based on SAS on-drug data is presented.","populationDescription":"Safety analysis set included all randomised subjects exposed to at least one dose of trial drug. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"events","timeFrame":"Week 0 to week 56+30 days","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"867"},{"groupId":"OG001","value":"601"}]}]}]},{"type":"SECONDARY","title":"Change in Physical Examination","description":"Observed change from baseline to week 56 in physical examination are categorised under parameters namely abdomen, gastrointestinal system, cardiovascular system, central and peripheral nervous system, general appearence, head, ears, eyes, nose, throat and neck, lymph node palpation, musculoskeletal system, respiratory system, skin and thyroid gland. The percentage of subjects assessed as normal, abnormal not clinically significant and abnormal clinically significant at baseline and week 56 is presented.","populationDescription":"Safety analysis set included all randomised subjects exposed to at least one dose of trial drug. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Week 1, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"title":"Abdomen (week -1) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"121"}]}]},{"title":"Abdomen (week -1) Abnormal, NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"19"}]}]},{"title":"Abdomen (week -1) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Abdomen (week 56) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"108"}]}]},{"title":"Abdomen (week 56) Abnormal, NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"12"}]}]},{"title":"Abdomen (week 56) Abnormal, CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"Gastrointestinal System (week -1) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"129"}]}]},{"title":"Gastrointestinal System (week -1) Abnormal NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"11"}]}]},{"title":"Gastrointestinal System (week -1) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Gastrointestinal System (week 56) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"132"},{"groupId":"OG001","value":"116"}]}]},{"title":"Gastrointestinal System (week 56) Abnormal NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"6"}]}]},{"title":"Gastrointestinal System (week 56) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Cardiovascular System (week-1) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"127"}]}]},{"title":"Cardiovascular System (week-1) Abnormal NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"13"}]}]},{"title":"Cardiovascular System (week-1) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Cardiovascular System (week 56) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"116"}]}]},{"title":"Cardiovascular System (week 56) Abnormal NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"}]}]},{"title":"Cardiovascular System (week 56) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Nervous System (week -1) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"127"}]}]},{"title":"Nervous System (week -1) Abnormal NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"}]}]},{"title":"Nervous System (week -1) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"7"}]}]},{"title":"Nervous System (week 56) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"132"},{"groupId":"OG001","value":"112"}]}]},{"title":"Nervous System (week 56) Abnormal NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"9"}]}]},{"title":"Nervous System (week 56) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"General Appearance (week -1) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"123"}]}]},{"title":"General Appearance (week -1) Abnormal NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"17"}]}]},{"title":"General Appearance (week -1) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"General Appearance (week 56) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"112"}]}]},{"title":"General Appearance (week 56) Abnormal NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"10"}]}]},{"title":"General Appearance (week 56) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Head, ENTand Neck (week -1) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"129"},{"groupId":"OG001","value":"128"}]}]},{"title":"Head, ENTand Neck (week -1) Abnormal NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"12"}]}]},{"title":"Head, ENTand Neck (week -1) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Head, ENTand Neck (week 56) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"115"}]}]},{"title":"Head, ENTand Neck (week 56) Abnormal NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"7"}]}]},{"title":"Head, ENTand Neck (week 56) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Lymph Node Palpation (week -1) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}]},{"title":"Lymph Node Palpation (week -1) Abnormal NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Lymph Node Palpation (week -1) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Lymph Node Palpation (week 56) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"121"}]}]},{"title":"Lymph Node Palpation (week 56) Abnormal NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Lymph Node Palpation (week 56) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Musculoskeletal System (week -1) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"131"},{"groupId":"OG001","value":"128"}]}]},{"title":"Musculoskeletal System (week -1) Abnormal NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"12"}]}]},{"title":"Musculoskeletal System (week -1) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Musculoskeletal System (week 56) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"112"}]}]},{"title":"Musculoskeletal System (week 56) Abnormal NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"}]}]},{"title":"Musculoskeletal System (week 56) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Respiratory System (week -1) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"140"},{"groupId":"OG001","value":"138"}]}]},{"title":"Respiratory System (week -1) Abnormal NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}]},{"title":"Respiratory System (week -1) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Respiratory System (week 56) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"120"}]}]},{"title":"Respiratory System (week 56) Abnormal NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}]},{"title":"Respiratory System (week 56) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Skin (week -1) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"114"}]}]},{"title":"Skin (week -1) Abnormal NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"24"}]}]},{"title":"Skin (week -1) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Skin (week 56) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"98"}]}]},{"title":"Skin (week 56) Abnormal NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"24"}]}]},{"title":"Skin (week 56) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Thyroid Gland (week -1) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"138"}]}]},{"title":"Thyroid Gland (week -1) Abnormal NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]}]},{"title":"Thyroid Gland (week -1) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Thyroid Gland (week 56) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"120"}]}]},{"title":"Thyroid Gland (week 56) Abnormal NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}]}]},{"title":"Thyroid Gland (week 56) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Change in Resting Pulse","description":"Observed mean change in pulse rate measured at resting position is presented.","populationDescription":"Safety analysis set included all randomised subjects exposed to at least one dose of trial drug. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"beats/min","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":"10"},{"groupId":"OG001","value":"1","spread":"10"}]}]}]},{"type":"SECONDARY","title":"Change in ECG","description":"The ECGs were interpreted by the investigator at baseline (week -1) and week 56 and categorised as normal, abnormal NCS or abnormal CS. Number of subjects in each ECG category at baseline and week 56 are presented.","populationDescription":"Safety analysis set included all randomised subjects exposed to at least one dose of trial drug. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Week -1, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"title":"Normal (week -1)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"91"}]}]},{"title":"Abnormal NCS (week -1)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"49"}]}]},{"title":"Abnormal CS (week -1)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Normal (week 56)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"124"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"102"},{"groupId":"OG001","value":"81"}]}]},{"title":"Abnormal NCS (week 56)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"124"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"42"}]}]},{"title":"Abnormal CS (week 56)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"124"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Change in Laboratory Measurements: Haematology (Haemoglobin Blood)","description":"Observed mean change from baseline in haematological parameter blood haemoglobin.","populationDescription":"Safety analysis set included all randomised subjects exposed to at least one dose of trial drug. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.5"},{"groupId":"OG001","value":"-0.1","spread":"0.6"}]}]}]},{"type":"SECONDARY","title":"Change in Laboratory Measurements: Haematology (Haematocrit Blood)","description":"Observed mean change from baseline in haematological parameter blood haematocrit. Haematocrit is presented as the percentage of red blood cells in total blood. Results based on SAS on-drug data is presented.","populationDescription":"Safety analysis set included all randomised subjects exposed to at least one dose of trial drug. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"percentage of red blood cells","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"2.3"},{"groupId":"OG001","value":"-0.9","spread":"2.6"}]}]}]},{"type":"SECONDARY","title":"Change in Laboratory Measurements: Haematology (Erythrocytes)","description":"Observed mean change from baseline in haematological parameter - erythrocytes.","populationDescription":"Safety analysis set included all randomised subjects exposed to at least one dose of trial drug. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"10^12 cells/L","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.11","spread":"0.25"},{"groupId":"OG001","value":"-0.08","spread":"0.25"}]}]}]},{"type":"SECONDARY","title":"Change in Laboratory Measurements: Haematology (Thrombocytes and Leukocytes)","description":"Observed mean change from baseline in haematological parameters - thrombocytss and leukocytes.","populationDescription":"Safety analysis set included all randomised subjects exposed to at least one dose of trial drug. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"10^9 cells/L","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"title":"Thrombocytes","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"101"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":"30"},{"groupId":"OG001","value":"0","spread":"36"}]}]},{"title":"Leukocytes","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"101"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.14","spread":"1.53"},{"groupId":"OG001","value":"-0.11","spread":"1.20"}]}]}]},{"type":"SECONDARY","title":"Change in Laboratory Measurements: Biochemistry (Albumin)","description":"Observed mean change from baseline in biochemical parameter - albumin. Results based on SAS on-drug data is presented.","populationDescription":"Safety analysis set included all randomised subjects exposed to at least one dose of trial drug. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"g/L","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.2"},{"groupId":"OG001","value":"-0.1","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Change in Laboratory Measurements: Biochemistry (Alkaline Phosphatase, Alanine Aminotransferase, Amylase, Aspartate Aminotransferase and Lipase)","description":"Observed mean change from baseline in biochemical parameters - alkaline phosphatase, alanine aminotransferase, amylase, aspartate aminotransferase and lipase. Results based on SAS on-drug data is presented.","populationDescription":"Safety analysis set included all randomised subjects exposed to at least one dose of trial drug. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"U/L","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"title":"Alkaline Phosphatase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"103"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2","spread":"12"},{"groupId":"OG001","value":"-1","spread":"13"}]}]},{"title":"Alanine Aminotransferase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"103"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5","spread":"14"},{"groupId":"OG001","value":"-4","spread":"16"}]}]},{"title":"Amylase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"103"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":"10"},{"groupId":"OG001","value":"1","spread":"13"}]}]},{"title":"Aspartate aminotransferase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"103"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3","spread":"10"},{"groupId":"OG001","value":"-2","spread":"12"}]}]},{"title":"Lipase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"103"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":"18"},{"groupId":"OG001","value":"2","spread":"22"}]}]}]},{"type":"SECONDARY","title":"Change in Laboratory Measurements: Biochemistry (Bilirubin and Creatinine)","description":"Observed mean change from baseline in biochemical parameters - bilirubin and creatinine. Results based on SAS on-drug data is presented.","populationDescription":"Safety analysis set included all randomised subjects exposed to at least one dose of trial drug. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"umol/L","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"title":"Bilirubin","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"103"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"3.2"},{"groupId":"OG001","value":"1.0","spread":"3.2"}]}]},{"title":"Creatinine","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"103"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"7.9"},{"groupId":"OG001","value":"-1.4","spread":"6.1"}]}]}]},{"type":"SECONDARY","title":"Change in Laboratory Measurements: Biochemistry (Total Calcium, Pottassium, Sodium and Urea)","description":"Observed mean change from baseline in biochemical parameters - total calcium, pottassium, sodium and urea. Results based on SAS on-drug data is presented.","populationDescription":"Safety analysis set included all randomised subjects exposed to at least one dose of trial drug. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"title":"Total Calcium","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"103"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.10"},{"groupId":"OG001","value":"0.01","spread":"0.09"}]}]},{"title":"Potassium","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"103"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"0.5"},{"groupId":"OG001","value":"-0.0","spread":"0.4"}]}]},{"title":"Sodium","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"103"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"2"},{"groupId":"OG001","value":"-0","spread":"2"}]}]},{"title":"Urea","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"103"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"1.2"},{"groupId":"OG001","value":"0.2","spread":"1.2"}]}]}]},{"type":"SECONDARY","title":"Change in Laboratory Measurements: Biochemistry (C-reactive Protein and Uric Acid)","description":"Observed mean change from baseline in biochemical parameters - high sensitive c-reactive protein and uric acid. Results based on SAS on-drug data is presented.","populationDescription":"Safety analysis set included all randomised subjects exposed to at least one dose of trial drug. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mg/dL","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"title":"High sensitive c-reactive protein","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"103"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.51","spread":"4.67"},{"groupId":"OG001","value":"-0.85","spread":"8.96"}]}]},{"title":"Uric acid","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"103"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"0.9"},{"groupId":"OG001","value":"-0.3","spread":"0.9"}]}]}]},{"type":"SECONDARY","title":"Change in Laboratory Measurements: Biochemistry (Glomerular Filtration Rate, Serum)","description":"Observed mean change from baseline in biochemical parameters - estimated glomerular filtration rate. Serum GFR is estimated using MDRD formula . Results based on SAS on-drug data is presented.","populationDescription":"Safety analysis set included all randomised subjects exposed to at least one dose of trial drug. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mL/min/1.73m^2","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":"11"},{"groupId":"OG001","value":"2","spread":"9"}]}]}]},{"type":"SECONDARY","title":"Change in Laboratory Measurements: Biochemistry (Calcitonin)","description":"Observed mean change from baseline in biochemical parameter - calcitonin. Results based on SAS on-drug data is presented.","populationDescription":"Safety analysis set included all randomised subjects exposed to at least one dose of trial drug. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng/L","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.8"},{"groupId":"OG001","value":"0.1","spread":"0.8"}]}]}]},{"type":"SECONDARY","title":"Change in Laboratory Measurements: Biochemistry (Thyroid Stimulating Hormone)","description":"Observed mean change from baseline in biochemical parameters - thyroid stimulating hormone. Results based on SAS on-drug data is presented.","populationDescription":"Safety analysis set included all randomised subjects exposed to at least one dose of trial drug. \"Number analysed\"=subjects with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mIU/L","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial."},{"id":"OG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2313","spread":"1.0366"},{"groupId":"OG001","value":"0.2685","spread":"3.6814"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"From the date of first dose of trial product (week 0) to end of treatment (week 56) + post treatment follow-up of 30 days.","description":"Evaluation of safety was based on safety analysis set (SAS) which comprised of all randomised subjects who received at least one dose of trial product.\n\nAEs with onset during the on-drug observation period (the period when subjects were exposed to trial product) were considered treatment-emergent.","eventGroups":[{"id":"EG000","title":"Lira 3.0 mg","description":"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until they reached a maintenance dose of 3.0 mg after 4 weeks. The treatment period was 56 weeks. Subjects were also on CMS-IBT during the trial.","deathsNumAffected":0,"deathsNumAtRisk":142,"seriousNumAffected":6,"seriousNumAtRisk":142,"otherNumAffected":124,"otherNumAtRisk":142},{"id":"EG001","title":"Placebo","description":"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. Subjects remained on a stable dose of placebo for 56 weeks. Subjects were also on CMS-IBT during the trial.","deathsNumAffected":0,"deathsNumAtRisk":140,"seriousNumAffected":2,"seriousNumAtRisk":140,"otherNumAffected":101,"otherNumAtRisk":140}],"seriousEvents":[{"term":"Ankle fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":142},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":140}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":142},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":140}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":142},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":140}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":142},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":140}]},{"term":"Hydrocephalus","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":142},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":140}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":142},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":140}]},{"term":"Ovarian cyst","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":142},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":140}]},{"term":"Papillary thyroid cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":142},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":140}]}],"otherEvents":[{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":142},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":140}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":9,"numAtRisk":142},{"groupId":"EG001","numEvents":20,"numAffected":16,"numAtRisk":140}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":8,"numAtRisk":142},{"groupId":"EG001","numEvents":14,"numAffected":13,"numAtRisk":140}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":57,"numAffected":43,"numAtRisk":142},{"groupId":"EG001","numEvents":34,"numAffected":26,"numAtRisk":140}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":142},{"groupId":"EG001","numEvents":11,"numAffected":9,"numAtRisk":140}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":47,"numAffected":31,"numAtRisk":142},{"groupId":"EG001","numEvents":26,"numAffected":23,"numAtRisk":140}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":9,"numAtRisk":142},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":140}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":8,"numAtRisk":142},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":140}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":13,"numAtRisk":142},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":140}]},{"term":"Gastroenteritis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":142},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":140}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":20,"numAtRisk":142},{"groupId":"EG001","numEvents":29,"numAffected":13,"numAtRisk":140}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":142},{"groupId":"EG001","numEvents":13,"numAffected":13,"numAtRisk":140}]},{"term":"Ligament sprain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":142},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":140}]},{"term":"Migraine","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":142},{"groupId":"EG001","numEvents":12,"numAffected":9,"numAtRisk":140}]},{"term":"Muscle strain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":142},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":140}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":13,"numAtRisk":142},{"groupId":"EG001","numEvents":13,"numAffected":9,"numAtRisk":140}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":102,"numAffected":68,"numAtRisk":142},{"groupId":"EG001","numEvents":33,"numAffected":25,"numAtRisk":140}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":142},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":140}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":9,"numAtRisk":142},{"groupId":"EG001","numEvents":20,"numAffected":18,"numAtRisk":140}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":38,"numAffected":32,"numAtRisk":142},{"groupId":"EG001","numEvents":17,"numAffected":15,"numAtRisk":140}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":8,"numAtRisk":142},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":140}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":47,"numAffected":33,"numAtRisk":142},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":140}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property."},"pointOfContact":{"title":"Clinical Reporting Anchor and Disclosure (1452)","organization":"Novo Nordisk A/S","email":"clinicaltrials@novonordisk.com","phone":"(+1) 866-867-7178"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2018-12-19","uploadDate":"2019-07-08T02:35","filename":"Prot_000.pdf","size":1589172},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2018-12-19","uploadDate":"2019-07-08T02:35","filename":"SAP_001.pdf","size":720475}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09"},"conditionBrowseModule":{"meshes":[{"id":"D009748","term":"Nutrition Disorders"},{"id":"D009765","term":"Obesity"}],"ancestors":[{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D050177","term":"Overweight"},{"id":"D044343","term":"Overnutrition"},{"id":"D001835","term":"Body Weight"},{"id":"D012816","term":"Signs and Symptoms"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069450","term":"Liraglutide"}],"ancestors":[{"id":"D052216","term":"Glucagon-Like Peptide 1"},{"id":"D004763","term":"Glucagon-Like Peptides"},{"id":"D052336","term":"Proglucagon"},{"id":"D005768","term":"Gastrointestinal Hormones"},{"id":"D006728","term":"Hormones"},{"id":"D006730","term":"Hormones, Hormone Substitutes, and Hormone Antagonists"}]}},"hasResults":true}